Characterization of the hdac/pi3k inhibitor cudc-907 as a novel senolytic

HIGHLIGHTS

• who: Saravanan from the Mechanisms of Cancer and Aging Laboratory, University of Leicester, Leicester , RH, United have published the research work: Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic, in the Journal: (JOURNAL)
• what: The authors show that CUDC-907 was indeed able to selectively induce apoptosis in cells driven to senesce by p53 expression but not when senescence happened in the absence of p53.
• how: Given the involvement of HDACs and the PI3K pathway in senescence the authors hypothesized that the dual inhibitor CUDC-907 a drug already . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.